ConductScience.org, home

Paper28477166

The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.

Tian F and 4 others. Eur Radiol, 2017. Cited by 58 papers, by iCite.

Cite this record

ConductScience Library. The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Papers, record 28477166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28477166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.
PubMed
Journal
Eur Radiol
PubMed
Year
2017
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
58
iCite
Relative citation ratio, by iCite
2.12
iCite
Revised in PubMed
2025-06-23
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tian FFangfang
2Shen GGuohua
3Deng YYunfu
4Diao WWei
5Jia ZZhiyun

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Fluorodeoxyglucose F18Major topic
Positron Emission Tomography Computed TomographyMajor topic
RadiopharmaceuticalsMajor topic
Breast
Chemotherapy, Adjuvant
Female
Humans
Lymph Nodes
Neoadjuvant Therapy
Odds Ratio
Sensitivity and Specificity

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
81571637National Natural Science Foundation of ChinaPubMed
81271532National Natural Science Foundation of ChinaPubMed

Source PubMed

Download CSV of grants

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124841218Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.Eur J Cancer2014https://conductscience.org/library/papers/24841218PubMed
224647576HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.Eur J Nucl Med Mol Imaging2014https://conductscience.org/library/papers/24647576PubMed
326953659Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.Clin Nucl Med2016https://conductscience.org/library/papers/26953659PubMed
423504954
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Cancer2013https://conductscience.org/library/papers/23504954PubMed
522499859Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.Ann Oncol2012https://conductscience.org/library/papers/22499859PubMed
611870173
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
J Clin Oncol2002https://conductscience.org/library/papers/11870173PubMed
726834099¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.J Nucl Med2016https://conductscience.org/library/papers/26834099PubMed
825476537TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.J Nucl Med2015https://conductscience.org/library/papers/25476537PubMed
925915099Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.Radiology2015https://conductscience.org/library/papers/25915099PubMed
1010673991
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
Eur J Cancer1999https://conductscience.org/library/papers/10673991PubMed
112633682118F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.Oncotarget2015https://conductscience.org/library/papers/26336821PubMed
1222438441Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.Radiology2012https://conductscience.org/library/papers/22438441PubMed
1325072926Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy.Clin Nucl Med2014https://conductscience.org/library/papers/25072926PubMed
1426205180Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.Mod Pathol2015https://conductscience.org/library/papers/26205180PubMed
153287615Measuring the accuracy of diagnostic systems.Science1988https://conductscience.org/library/papers/3287615PubMed
162183008718F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.Int J Clin Oncol2012https://conductscience.org/library/papers/21830087PubMed
178622014Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.J Clin Oncol1996https://conductscience.org/library/papers/8622014PubMed
182273408018F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.Acta Radiol2012https://conductscience.org/library/papers/22734080PubMed
1919877158The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.J Surg Oncol2010https://conductscience.org/library/papers/19877158PubMed
208229124Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.J Clin Oncol1993https://conductscience.org/library/papers/8229124PubMed

See all 55 referencesDownload CSV of references

Cited by48

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 58 citations.

PMIDTitleJournalYearIn PapersSource
42793693Association of PET/CT-Derived Metabolic Parameters with Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: An Analysis Across Molecular Subtypes.Diagnostics (Basel)2026https://conductscience.org/library/papers/42793693PubMed
42230653Diagnostic Performance of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer.NPJ Breast Cancer2026https://conductscience.org/library/papers/42230653PubMed
42165827FDG PET Hybrid Imaging.Recent Results Cancer Res2026https://conductscience.org/library/papers/42165827PubMed
42089524The Future of Quantitative Breast Imaging: Integrated to Integral Imaging Biomarkers for Precision Cancer Care, From the AJR Special Series on Quantitative Imaging.AJR Am J Roentgenol2026https://conductscience.org/library/papers/42089524PubMed
42035386Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.EJNMMI Radiopharm Chem2026https://conductscience.org/library/papers/42035386PubMed
41944968A narrative review: key evidence from meta-analyses in nuclear medicine.Ann Nucl Med2026https://conductscience.org/library/papers/41944968PubMed
41922613[68Ga]Ga-HER2 Affibody PET/CT for early prediction of neoadjuvant therapy outcome in HER2-positive breast cancer: a preliminary report.EJNMMI Res2026https://conductscience.org/library/papers/41922613PubMed
41901569Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.Medicina (Kaunas)2026https://conductscience.org/library/papers/41901569PubMed
39692805Does FDG PETCT have a predictive value for neoadjuvant chemotherapy response in nonmetastatic breast cancer?Ir J Med Sci2025https://conductscience.org/library/papers/39692805PubMed
39338206
Peritumoral Adipose Tissue Features Derived from [18F]fluoro-2-deoxy-2-d-glucose Positron Emission Tomography/Computed Tomography as Predictors for Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
J Pers Med2024https://conductscience.org/library/papers/39338206PubMed
39161537Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer?Respirol Case Rep2024https://conductscience.org/library/papers/39161537PubMed
3912925018F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting.Acta Oncol2024https://conductscience.org/library/papers/39129250PubMed
38989317Fluorine-18 FDG PET/CT and New NIMS Grading System for Chemotherapy Response in Breast Cancer.Indian J Nucl Med2024https://conductscience.org/library/papers/38989317PubMed
38929989PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.J Clin Med2024https://conductscience.org/library/papers/38929989PubMed
38740576Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).Eur J Nucl Med Mol Imaging2024https://conductscience.org/library/papers/38740576PubMed
38304900
More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial.
Ann Transl Med2024https://conductscience.org/library/papers/38304900PubMed
38202160Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.J Clin Med2023https://conductscience.org/library/papers/38202160PubMed
37958390Impact of Imaging Biomarkers and AI on Breast Cancer Management: A Brief Review.Cancers (Basel)2023https://conductscience.org/library/papers/37958390PubMed
3791886668Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.J Nucl Med2023https://conductscience.org/library/papers/37918866PubMed
37746288The potential role of combined shear wave elastography and superb microvascular imaging for early prediction the pathological response to neoadjuvant chemotherapy in breast cancer.Front Oncol2023https://conductscience.org/library/papers/37746288PubMed

See all 48 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28477166

GET https://conductscience.org/api/papers/v1/28477166/references?page=2